Germany-headquartered drug manufacturer Evotec SE (EVT,EVO) on Thursday announced progress in the company's strategic partnership with U.S.-based drug manufacturer Bristol Myers Squibb (BMY) that would further bolster the joint pipeline of advanced neuroscience programmes.
Evotec would receive a payment of $25 million to progress further research.
Evotec and Bristol Myers Squibb had started their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. In March 2023, the two companies expanded their partnership for an additional 8 years.
The progress announced here leverages Evotec's PanOmics platform in conjunction with patient-derived disease models. The PanOmics-driven drug discovery platform is being targeted on neurodegenerative diseases with tremendous unmet medical need.
The partnership has generated a promising pipeline of discovery to clinical-stage programmes. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.